
Captor Therapeutics, a biopharmaceutical company, uses targeted protein degradation and its Optigrade platform to select target-ligase pairs for lead-quality molecules.
captortherapeutics.comCrawled Nov 10, 2026
Captor Therapeutics is a high-tech pharmaceutical company focused on targeting the undruggable proteome.
Captor Therapeutics receives a $2 million non-dilutive grant from The Michael J. Fox Foundation to advance its brain-penetrant NEK7 candidate. The funding supports research into neurodegenerative diseases, including Parkinson’s. The company uses the award to further develop its stock-backed project.
Wolf Theiss advises the **European Innovation Council Fund (EIC Fund)** on its Series Y share subscription in **Captor Therapeutics**, a biopharmaceutical company focused on **targeted protein degradation (TPD) technology**. The EIC Fund, backed by the **European Commission**, invests in newly issued shares of Captor Therapeutics to support its development efforts. The transaction highlights the growing interest in innovative biotech solutions within Europe.
Captor Therapeutics reveals the molecular targets for its lead drug candidates **CT-01, CT-02, and CT-05**, all based on its **Targeted Protein Degradation (TPD) platform**. The company provides supporting data and updates on research progress for these programs, advancing its pipeline in protein degradation therapies. Stakeholders are invited to a webcast for further details.
Ono Pharmaceutical and Captor Therapeutics collaborate to develop small-molecule protein degraders targeting neurodegenerative diseases. The partnership focuses on advancing drug discovery in this therapeutic area using Captor’s proprietary technology platform. Both companies aim to leverage their expertise to address unmet medical needs in neurodegenerative conditions.
Captor Therapeutics selects a lead drug candidate targeting **hepatocellular carcinoma**, a primary liver cancer. The Polish biopharma specializes in oncology and autoimmune disease therapies. This marks a key development in its pipeline for liver cancer treatments.
Captor Therapeutics demonstrates preclinical efficacy of its CT-01 program, a targeted protein degradation therapy for hepatocellular carcinoma (HCC). The company reports in vivo proof-of-concept data showing potential tumor suppression in animal models. CT-01 is part of Captor’s pipeline of TPD-based treatments for cancer and autoimmune diseases.